Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

EGFR Gene Mutation Clinical Trial

— APPEAL  

Official title:

Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04592666
• Other study ID #: ALMO-PEME-CAR-01
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 9, 2020
• Est. completion date: June 30, 2022

Study information

• Verified date: October 2020
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 226
• Est. completion date: June 30, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Between 18 and 75 years old (including 18 and 75 years old);

2. Histologically or cytologically confirmed locally advanced or metastatic (STAGE IIIB-IV) NSCLC does not accept simple sputum smear-based diagnosis;

3. Previous genetic tests confirmed egFR-sensitive mutations, and received one or two generations of EGFR TKI treatment. After drug resistance, it was confirmed to be positive for EGFR T790M mutation by biopsy or free DNA test.

4. The patient has at least one tumor lesion that has not received local treatment such as radiation or biopsy in the screening stage, and can be accurately measured at baseline, with the longest diameter = 10mm at baseline (short diameter = 15mm if lymph nodes are involved).The measurement method chosen is suitable for accurate repeated measurements and can be computed tomography (CT) or magnetic resonance imaging (MRI).If there is only one measurable lesion and no previous local treatment such as irradiation, it can be accepted as the target lesion for baseline evaluation of tumor lesions after at least 14 days of diagnostic biopsy.

5. Life expectancy is at least 3 months;

6. ECOG score: 0-1, with no significant clinical deterioration in the past 2 weeks;

7. The main organs function normally, that is, they meet the following standards:

blood routine examination standards must be in accordance with no blood transfusion and adjuvant therapies (14 days) : A. Hemoglobin (HB) =90 g/L; B. Absolute value of neutrophils (ANC) =1.5×109/L; C. Platelet (PLT) =100×109/L; D. Total bilirubin (TBIL) <1.5 times the upper limit of normal value (ULN); E. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5×ULN, if accompanied by liver metastasis, ALT and AST< 5×ULN; F. Serum Cr<1.25×ULN or endogenous creatinine clearance rate (CCr) > 45 ml/min (Cockcroft-Gault formula);

Exclusion Criteria:

1. Patients who have received three generations of EGFR-TKI treatment;

2. Patients with mixed small cell lung cancer components;

3. Patients with advanced or metastatic disease who have received palliative chemotherapy, or patients with tumor recurrence and metastasis within 6 months after radical surgery with adjuvant chemotherapy;

4. Patients with symptomatic brain metastasis, meningeal metastasis or spinal cord compression;

5. Patients with previous diagnosis of interstitial pneumonia;

6. Uncontrolled hypertension (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg, despite the best medication);

7. with severe cardiovascular disease: ? magnitude of myocardial ischemia and myocardial infarction, poor control of cardiac arrhythmias (including QTc interphase male 450, female 470 ms or ms or higher);According to NYHA standard, ? ~ ? cardiac insufficiency, or heart colour to exceed revealed left ventricular ejection fraction (LVEF) < 50%;

8. abnormal coagulation function (INR >1.5 or prothrombin time (PT) > ULN+4 seconds or APTT > 1.5uln), bleeding tendency or receiving thrombolytic or anticoagulant therapy; Note: Under the condition that the international standard ratio of prothrombin time (INR) =1.5, low-dose heparin (daily dosage for adults ranges from 66,000 to 12,000 U) or low-dose aspirin (daily dosage =100 mg) is allowed for preventive purposes.

9. Peripheral neuropathy =CTCAE 2 is present, except for trauma;

10. Respiratory syndrome (=CTCAE level 2 dyspnea), uncontrolled serous cavity effusion (including pleural effusion, ascites and pericardial effusion);

11. A wound or fracture that has not been healed for a long time;

12. Severe infections requiring systemic antibiotics;

13. Decompensated diabetes mellitus or other contraindications of high-dose glucocorticoid therapy;

14. Active hepatitis C and/or hepatitis B infection (hepatitis B: HBsAg positive with HBV DNA=500IU/mL;Hepatitis C: HCV RNA positive);

15. Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction;

16. Had major surgery or severe traumatic injury, fracture or ulcer within the first 4 weeks;

17. Any contraindications for platinum (carboplatin) and cytotoxic drug (Pemetrexed) treatment;

18. Other conditions deemed inappropriate by the researcher for inclusion in the study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• EGFR Gene Mutation
• EGFR T790M
• Lung Cancer, Non-small Cell
• Lung Neoplasms

Intervention

Drug:
• Almonertinib
the standard therapy of single agent almonertinib
• Pemetrexed
standard dose
• Carboplatin
AUC=5

Locations

Country	Name	City	State
China	Cancer hospital Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	progression free survival	from the first cycle of treatment (day one) to two month after the last cycle (each cycle is 21 days)